Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0193)
Name
Dihydrotanshinone I
Synonyms
Dihydrotanshinone I; 87205-99-0; 15,16-dihydrotanshinone I; DihydrotanshinoneI; (-)-Dihydrotanshinone I; Dihydrotanshinone-I; Tanshinone I, dihydro-; HSDB 8105; UNII-562G9360V6; 562G9360V6; DTXSID20236187; (1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione; DIHYDROTANSHINONE I, (-)-; DIHYDROTANSHINONE; (1R)-1,6-Dimethyl-1,2-dihydrophenanthro(1,2-b)furan-10,11-dione; (R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione; PHENANTHRO(1,2-B)FURAN-10,11-DIONE, 1,2-DIHYDRO-1,6-DIMETHYL-, (1R)-; SR-05000002191; 15,16-dihydrotanshinone-I; (1R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione; DHTS; 4m0e; CHEMBL227075; SCHEMBL13049977; DTXCID20158678; CHEBI:149872; HARGZZNYNSYSGJ-JTQLQIEISA-N; HY-N0360; BDBM50423877; MFCD28016070; s9020; AKOS032962078; CCG-208567; Dihydrotanshinone I, >=98% (HPLC); NCGC00163651-01; NCGC00163651-06; D5379; A862726; SR-05000002191-2; SR-05000002191-3; Q21099654; DIHYDROTANSHINONE (CONSTITUENT OF CHINESE SALVIA); DIHYDROTANSHINONE (CONSTITUENT OF CHINESE SALVIA) [DSC]; '(1R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione'; (-)-1,2-Dihydro-1,6-dimethylphenanthro[1,2-b]furan-10,11-dione;1,6-Dimethyl-1,2,10,11-tetrahydrophenanthro[1,2-b]furan-10,11-dione;4,17-Dimethyl-15-oxagona-1,3,5(10),6,8,13-hexene-11,12-dione;15,16-Dihydrotanshine I;1,6-DiMethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione

    Click to Show/Hide
Structure
Formula
C18H14O3
IUPAC Name
(1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione
Canonical SMILES
CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C
InChI
InChI=1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3/t10-/m0/s1
InChIKey
HARGZZNYNSYSGJ-JTQLQIEISA-N
PubChem CID
11425923
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Glioblastoma ICD-11: 2A00
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HEB (Human glial cells)
U87 MG-Red-Fluc cells Glioblastoma Homo sapiens CVCL_5J12
U-251MG cells Astrocytoma Homo sapiens CVCL_0021
Response regulation Dihydrotanshinone I (DHI) inhibited the proliferation of human glioma cells. Following treatment of the U251 and U87 cells with DHI, changes in the expression levels of ferroptosis-associated proteins were observed; the expression level of GPX4 decreased and that of ACSL-4 increased. DHI also increased the levels of LDH and MDA in the human glioma cells and reduced the GSH/GSSG ratio.
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Glioblastoma ICD-11: 2A00
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HEB (Human glial cells)
U87 MG-Red-Fluc cells Glioblastoma Homo sapiens CVCL_5J12
U-251MG cells Astrocytoma Homo sapiens CVCL_0021
Response regulation Dihydrotanshinone I (DHI) inhibited the proliferation of human glioma cells. Following treatment of the U251 and U87 cells with DHI, changes in the expression levels of ferroptosis-associated proteins were observed; the expression level of GPX4 decreased and that of ACSL-4 increased. DHI also increased the levels of LDH and MDA in the human glioma cells and reduced the GSH/GSSG ratio.
References
Ref 1 Dihydrotanshinone I inhibits human glioma cell proliferation via the activation of ferroptosis. Oncol Lett. 2020 Oct;20(4):122. doi: 10.3892/ol.2020.11980. Epub 2020 Aug 13.